Cargando…
CYP11B1 has no role in mitotane action and metabolism in adrenocortical carcinoma cells
Mitotane is the reference drug for adrenocortical carcinoma (ACC) and the metabolic activation of the drug is considered as essential for its activity. The aim of this study was to assess the role of CYP11B1 on mitotane action and metabolism in H295R ACC cells to understand whether this enzyme may i...
Autores principales: | Germano, Antonina, Saba, Laura, De Francia, Silvia, Rapa, Ida, Perotti, Paola, Berruti, Alfredo, Volante, Marco, Terzolo, Massimo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5937768/ https://www.ncbi.nlm.nih.gov/pubmed/29734384 http://dx.doi.org/10.1371/journal.pone.0196931 |
Ejemplares similares
-
Involvement of 27-Hydroxycholesterol in Mitotane Action on Adrenocortical Carcinoma
por: Germano, Antonina, et al.
Publicado: (2020) -
Molecular Mechanisms of Mitotane Action in Adrenocortical Cancer Based on In Vitro Studies
por: Lo Iacono, Marco, et al.
Publicado: (2021) -
Unwanted Hormonal and Metabolic Effects of Postoperative Adjuvant Mitotane Treatment for Adrenocortical Cancer
por: Basile, Vittoria, et al.
Publicado: (2020) -
What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question
por: Basile, Vittoria, et al.
Publicado: (2021) -
Mitotane Concentrations Influence Outcome in Patients with Advanced Adrenocortical Carcinoma
por: Puglisi, Soraya, et al.
Publicado: (2020)